Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Cutting the red tape with buprenorphine treatment for opioid use disorder

Christina Kinnevey, MD
Meds
April 10, 2018
Share
Tweet
Share

Tuesday morning. Sarah wakes up at 4 a.m., like every other morning, to go to clinic to get a medicine she cannot function without.  But it’s not as easy as that. She has to take her three small children with her because she is a single parent and has no one else to stay at home with them.  She does this six days a week. This is her life. This is the reality of methadone clinics, and as a family physician, I worry about the impact this is having on the health and well-being of her family.

The opioid epidemic is increasingly being recognized as one of the largest health care problems facing our nation, and medication-assisted treatment, like methadone, is often at the forefront of discussion.  While methadone is a highly effective treatment, more attention needs to be paid to the other FDA approved medication for opioid use disorder, buprenorphine.

As a dual buprenorphine and methadone provider, I have a unique ability to compare these treatment modalities.  The evidence and my experience is that buprenorphine is superior across the board in ease of use, withdrawal profile, risk of abuse, dangerous side effects and above all, risk of overdose. As a strong partial agonist of the opioid Mu receptor, buprenorphine has a ceiling effect such that there is almost no risk of overdose, even in combination with other opioids.  This is not the case with methadone for opioid addiction, which is reason why it is so highly regulated through specific methadone clinics.  While the structure of methadone clinics might benefit some patients, for many patients, like Sarah, it is an almost an insurmountable barrier.

Now if Sarah is lucky and motivated, she might have heard about buprenorphine and desire to give it a try, so she doesn’t have to wake her kids up at 4 a.m. every day.  But then comes her next challenge.  She has to find an “X-waivered” provider, or someone licensed to prescribe buprenorphine.    As of 2015, only 3 percent of primary care physicians in the U.S. have such prescribing privileges.  The majority of rural counties in the U.S. have no X-waivered providers. In order to receive an X-waiver, physicians have to complete eight hours of additional training, and mid-level providers have to complete an additional 24 hours.

My question is why do these regulations exist at all?  As a physician, I can graduate my internship and prescribe as much Norco, Vicodin, Percocet, Oxycontin, Morphine, Fentanyl and even methadone that I deem necessary to treat pain with absolutely no additional training.  These medications carry extremely high risks for side effects, misuse, and overdose leading to death.  Yet when my patients get addicted to these medications, I cannot immediately offer them the much safer alternative opioid, buprenorphine, to treat their addiction.  Furthermore, even if I do go through the training and legal process to get my X-waiver, I am still restricted in the number of patients for whom I can treat with buprenorphine; 30 in the first year and 100 in the year after that.  Meticulous bookkeeping is required to keep count of these patients should we ever get audited by the DEA, increasing administrative burden.

The Drug Addiction Treatment Act of 2000 was a huge step forward in increasing access to buprenorphine in the outpatient setting by allowing physicians with an X-waiver to prescribe buprenorphine.  Now that we have nearly two decades of clinical experience to show that buprenorphine MAT can be done safely and effectively in the outpatient setting, I argue that we don’t need to require providers to obtain an X-waiver anymore.

The opioid epidemic has been declared a national health emergency, and this extra regulation for providers is simply another barrier to addressing the problem.  I urge my medical colleagues to pressure their legislators to create common sense laws that will allow buprenorphine, in conjunction with standard addiction behavior therapy, to be prescribed in all outpatient clinics without all the cumbersome regulations that currently deter many physicians.

Christina Kinnevey is a family physician.

Image credit: Shutterstock.com

Prev

A case for climate activism: but where are the medical students?

April 10, 2018 Kevin 23
…
Next

Take 2 broccoli and call me in the morning

April 10, 2018 Kevin 3
…

Tagged as: Pain Management, Primary Care

Post navigation

< Previous Post
A case for climate activism: but where are the medical students?
Next Post >
Take 2 broccoli and call me in the morning

ADVERTISEMENT

Related Posts

  • Allow patients to continue their opioid of choice while starting microdoses of buprenorphine

    Julie Craig, MD
  • The pandemic’s epidemic: opioid use disorder and subpar suboxone access   

    Jonathan Staloff, MD and Claire Simon, MD
  • Don’t let the opioid crisis affect the treatment course for your patients

    T.J. Matsumoto, PA-C
  • Stop stigmatizing medication-assisted treatment

    Brandon Jacobi
  • The confusing policy surrounding the buprenorphine X-waiver

    Julie Craig, MD
  • The other opioid epidemic that we ignore

    Hans Duvefelt, MD

More in Meds

  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • The food-drug interaction risks your doctor may be missing

    Frank Jumbe
  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • Most Popular

  • Past Week

    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
  • Past 6 Months

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
    • Why Medicaid cuts should alarm every doctor

      Ilan Shapiro, MD | Policy
  • Recent Posts

    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Decoding your medical bill: What those charges really mean

      Cheryl Spang | Finance
    • The emotional first responders of aesthetic medicine

      Sarah White, APRN | Conditions
    • Why testosterone matters more than you think in women’s health

      Andrea Caamano, MD | Conditions
    • A mind to guide the machine: Why physicians must help shape artificial intelligence in medicine

      Shanice Spence-Miller, MD | Tech
    • How subjective likability practices undermine Canada’s health workforce recruitment and retention

      Olumuyiwa Bamgbade, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 5 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
  • Past 6 Months

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
    • Why Medicaid cuts should alarm every doctor

      Ilan Shapiro, MD | Policy
  • Recent Posts

    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Decoding your medical bill: What those charges really mean

      Cheryl Spang | Finance
    • The emotional first responders of aesthetic medicine

      Sarah White, APRN | Conditions
    • Why testosterone matters more than you think in women’s health

      Andrea Caamano, MD | Conditions
    • A mind to guide the machine: Why physicians must help shape artificial intelligence in medicine

      Shanice Spence-Miller, MD | Tech
    • How subjective likability practices undermine Canada’s health workforce recruitment and retention

      Olumuyiwa Bamgbade, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Cutting the red tape with buprenorphine treatment for opioid use disorder
5 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...